|
Reference
|
|
*** (2013) Hypertension in pregnancy: Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol, 122(5): 1122-31
|
|
August, P., Sibai, B.M. (2019) Preeclampsia: Clinical features and diagnosis. UpToDate
|
1
|
Barrett, J.C., Fry, B., Maller, J., Daly, M.J. (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England), 21(2): 263-265
|
|
Catella, F., Lawson, J.A., Fitzgerald, D.J., Fitzgerald, G.A. (1990) Endogenous biosynthesis of arachidonic acid epoxides in humans: Increased formation in pregnancy-induced hypertension. Proceedings of the National Academy of Sciences, 87(15): 5893-5897
|
|
Corenblum, M.J., Wise, V.E., Georgi, K., Hammock, B.D., Doris, P.A., Fornage, M. (2008) Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension, 51(2): 567-573
|
|
Dai, M., Wu, L., Tu, L., Xu, X., Wang, D.W. (2018) The immune-metabolic regulatory roles of epoxyeicosatrienoic acids on macrophages phenotypic plasticity in obesity-related insulin resistance. Prostaglandins & Other Lipid Mediators, 139: 36-40
|
|
Decker, M., Arand, M., Cronin, A. (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Archives of Toxicology, 83(4): 297-318
|
|
Fava, C., Ricci, M., Melander, O., Minuz, P. (2012) Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?. Prostaglandins & Other Lipid Mediators, 98(3-4): 75-85
|
|
Fava, C., Montagnana, M., Danese, E., Almgren, P., Hedblad, B., Engström, G., Berglund, G., Minuz, P., Melander, O. (2010) Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: A study in Swedes. Pharmacogenetics and Genomics, 20(2): 94-103
|
|
Fisslthaler, B., Popp, R., Kiss, L., Potente, M., Harder, D.R., Fleming, I., Busse, R. (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 401(6752): 493-497
|
|
Giachini, F.R., Galaviz-Hernandez, C., Damiano, A.E., Viana, M., Cadavid, A., Asturizaga, P., Teran, E., Clapes, S., Alcala, M., Bueno, J., Calderón-Domínguez, M., Ramos, M.P., Lima, V.V. (2017) Vascular dysfunction in mother and offspring during preeclampsia: Contributions from Latin-American countries. Current Hypertension Reports, 19(10): 83-83
|
|
Herse, F., Lamarca, B., Hubel, C.A., Kaartokallio, T., Lokki, A. I., Ekholm, E., Laivuori, H., Gauster, M., Huppertz, B., Sugulle, M., Ryan, M.J., Novotny, S., Brewer, J., Park, J., Kacik, M. (2012) Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation, 126(25): 2990-2999
|
|
Inceoglu, B., Bettaieb, A., Trindade, da S.C.A., Lee, K.S.S., Haj, F.G., Hammock, B.D. (2015) Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proceedings of the National Academy of Sciences, 112(29): 9082-9087
|
|
Iyer, A., Kauter, K., Alam, A., Hwang, S.H., Morisseau, C., Hammock, B.D., Brown, L. (2012) Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Experimental Diabetes Research, 2012: 1-11, 758614
|
|
Jiang, H., Mcgiff, J.C., Fava, C., Amen, G., Nesta, E., Zanconato, G., Quilley, J., Minuz, P. (2013) Maternal and fetal epoxyeicosatrienoic acids in normotensive and preeclamptic pregnancies. American Journal of Hypertension, 26(2): 271-278
|
|
Keserü, B., Barbosa-Sicard, E., Schermuly, R.T., Tanaka, H., Hammock, B.D., Weissmann, N., Fisslthaler, B., Fleming, I. (2010) Hypoxia-induced pulmonary hypertension: Comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovascular Research, 85(1): 232-240
|
|
Kompa, A.R., Wang, B.H., Xu, G., Zhang, Y., Ho, P., Eisennagel, S., Thalji, R.K., Marino, J.P., Kelly, D.J., Behm, D.J., Krum, H. (2013) Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. International Journal of Cardiology, 167(1): 210-219
|
|
Lamarca, B., Cornelius, D.C., Harmon, A.C., Amaral, L.M., Cunningham, M.W., Faulkner, J.L., Wallace, K. (2016) Identifying immune mechanisms mediating the hypertension during preeclampsia. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 311(1): R1-R9
|
|
Lee, C.R., North, K.E., Bray, M.S., Fornage, M., Seubert, J.M., Newman, J.W., Hammock, B.D., Couper, D.J., Heiss, G., Zeldin, D.C. (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Human Molecular Genetics, 15(10): 1640-1649
|
|
Li, D., Liu, Y., Zhang, X., Lv, H., Pang, W., Sun, X., Gan, L., Hammock, B.D., Ai, D., Zhu, Y. (2016) Inhibition of soluble epoxide hydrolase alleviated atherosclerosis by reducing monocyte infiltration in Ldlr(-/-) mice. Journal of Molecular and Cellular Cardiology, 98: 128-137
|
|
Liu, X., Wu, J., Liu, H., Lai, G., Zhao, Y. (2012) Disturbed ratio of renal 20-HETE/EETs is involved in androgen-induced hypertension in cytochrome P450 4F2 transgenic mice. Gene, 505(2): 352-359
|
|
Morgan, T., Ward, K. (1999) New insights into the genetics of preeclampsia. Seminars in Perinatology, 23(1): 14-23
|
|
Nakadera, Y., Kunita, K., Serizawa, T., Aoki, T., Nishimura, Y., Yamada, M. (2016) Effect of novel soluble epoxide hydrolase inhibitor against to pulmonary arterial hypertensive rats. Journal of Cardiac Failure, 22(9): S198-S198
|
|
Node, K., Huo, Y., Ruan, X., i dr. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 285(5431): 1276-1279
|
|
Plenty, N.L., Faulkner, J.L., Cotton, J., Spencer, S., Wallace, K., Lamarca, B., Murphy, S.R. (2018) Arachidonic acid metabolites of CYP4A and CYP4F are altered in women with preeclampsia. Prostaglandins & Other Lipid Mediators, 136: 15-22
|
1
|
Rajendran, P., Rengarajan, T., Thangavel, J., Nishigaki, Y., Sakthisekaran, D., Sethi, G., Nishigaki, I. (2013) The vascular endothelium and human diseases. International Journal of Biological Sciences, 9(10): 1057-1069
|
|
Santos, J.M., Park, Jung-A., Joiakim, A., Putt, D.A., Taylor, R.N., Kim, H. (2017) The role of soluble epoxide hydrolase in preeclampsia. Medical Hypotheses, 108: 81-85
|
|
Sari, I., Pinarbasi, H., Pinarbasi, E., Yildiz, C. (2017) Association between the soluble epoxide hydrolase gene and preeclampsia. Hypertension in Pregnancy, 36(4): 315-325
|
|
Sari, I., Pınarbaşı, H., Yıldız, Ç. (2018) Epoxyeicosatrienoic acid metabolism in preeclampsia. Cumhuriyet Medical Journal / Cumhuriyet Tıp Dergisi, 40(4): 454-60
|
|
Tacconelli, S., Patrignani, P. (2014) Inside epoxyeicosatrienoic acids and cardiovascular disease. Frontiers in Pharmacology, 5: 239-239
|
|
Tu, R., Armstrong, J., Lee, K.S.S., Hammock, B.D., Sapirstein, A., Koehler, R.C. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Scientific Reports, 8(1): 5279-5279
|
|
Wang, A., Rana, S., Karumanchi, S. A. (2009) Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology, 24(3): 147-158
|
|
Zhang, D., Ai, D., Tanaka, H.D., Hammock, B.D., Zhu, Y. (2010) DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1799(9): 659-667
|
|
Zheng, X., Zinkevich, N.S., Gebremedhin, D., Gauthier, K.M., Nishijima, Y., Fang, J., Wilcox, D.A., Campbell, W.B., Gutterman, D.D., Zhang, D.X. (2013) Arachidonic acid-induced dilation in human coronary arterioles: Convergence of signaling mechanisms on endothelial TRPV4-mediated Ca 2+ entry. Journal of the American Heart Association, 2(3): e000080
|
|
Zhou, Y., Chang, H., Du, J., Wang, C., Dong, Z., Wang, M. (2005) Renal epoxyeicosatrienoic acid synthesis during pregnancy. American Journal of Physiology-Renal Physiology, 288(1): F221-F226
|
|
Zordoky, B.N.M., El-Kadi, A.O.S. (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacology & Therapeutics, 125(3): 446-463
|
|
|
|